Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

Results of the PEACE-1 open-label, randomized, controlled, phase III trial have been published in The Lancet. In this study, the efficacy and safety of adding prostate radiotherapy to the treatment regimen in de novo metastatic castration-sensitive prostate cancer was investigated. In total, 1,172 men were randomly assigned to receive standard of care or standard of care plus abiraterone, plus radiotherapy or plus abiraterone and radiotherapy.

PEACE-1开放标签，随机，对照，III期试验的结果已发表在《柳叶刀》上。在这项研究中，研究了在从头转移性去势敏感性前列腺癌的治疗方案中加入前列腺放疗的有效性和安全性。总共有1172名男性被随机分配接受标准护理或标准护理加阿比特龙，加放疗或加阿比特龙和放疗。

After a median follow-up duration of 6 years, radiographic progression-free and castration-free survival were improved for men who received standard of care plus abiraterone and radiotherapy. However, overall survival was not affected..

中位随访时间为6年后，接受标准护理加阿比特龙和放疗的男性的放射学无进展和无去势生存率得到改善。然而，总体生存率没有受到影响。。

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Access Nature and 54 other Nature Portfolio journals

Access Nature和54种其他Nature投资组合期刊

Get Nature+, our best-value online-access subscription

获取Nature+，我们最具价值的在线访问订阅

24,99 € / 30 days

24,99欧元/30天

cancel any time

随时取消

Learn more

了解更多信息

Subscription info for Chinese customersWe have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.Go to naturechina.com

中国客户的订阅信息我们为中国客户提供了一个专门的网站。请访问naturechina.com订阅本期刊。访问naturechina.com

Buy this article

购买这篇文章

Purchase on SpringerLink

在SpringerLink上购买

Instant access to full article PDF

即时访问全文PDF

Buy now

立即购买

Prices may be subject to local taxes which are calculated during checkout

价格可能需要缴纳结帐时计算的地方税

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

ReferencesOriginal articleBossi, A. et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet https://doi.org/10.1016/S0140-6736(24)01865-8 (2024)Article .

。柳叶刀https://doi.org/10.1016/S0140-6736（24）01865-8（2024）条。

PubMed

PubMed

Google Scholar

谷歌学者

Download referencesAuthor informationAuthors and AffiliationsNature Reviews Urology http://www.nature.com/nrurol/Louise LloydAuthorsLouise LloydView author publicationsYou can also search for this author in

下载参考文献作者信息作者和附属机构泌尿外科评论http://www.nature.com/nrurol/LouiseLloydAuthorsLouise LloydView作者出版物您也可以在

PubMed Google ScholarCorresponding authorCorrespondence to

PubMed谷歌学者通讯社

Louise Lloyd.Rights and permissionsReprints and permissionsAbout this articleCite this articleLloyd, L. PEACEing together prostate cancer therapy.

路易丝·劳埃德。权利和许可打印和许可本文引用本文Lloyd，L。Peacing together prostate cancer therapy。

Nat Rev Urol (2024). https://doi.org/10.1038/s41585-024-00982-9Download citationPublished: 06 December 2024DOI: https://doi.org/10.1038/s41585-024-00982-9Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Nat Rev Urol（2024年）。https://doi.org/10.1038/s41585-024-00982-9Download引文发布日期：2024年12月6日OI：https://doi.org/10.1038/s41585-024-00982-9Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供